Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintains a Buy rating on Aprea Therapeutics, with a $10.00 price target, due to advancements in its synthetic lethality programs. The company's ATRN-119 and APR-1051 programs show promising safety and efficacy in trials. Aprea's financial stability supports ongoing development, with key data expected in 2026. McCarthy's confidence in Aprea's potential is reflected in his rating, despite his average return of -14.4% and a 33.20% success rate on stocks.

Aprea Therapeutics Reports Ongoing Financial Challenges

Aprea Therapeutics, Inc. (APRE) reported ongoing financial challenges in its Q3 earnings, highlighting a net loss of approximately $10.1 million for the nine months ending September 30, 2025. The company experienced a decrease in cash reserves, with cash and cash equivalents at $13.7 million, raising concerns about funding operations beyond the next twelve months. Aprea is actively seeking additional funding to support its clinical trials and is focused on advancing its product candidates while exploring strategic opportunities to improve its financial position.

Aprea Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.848 K

Aprea Therapeutics' Q3 net loss narrows

Aprea Therapeutics reported a narrowed Q3 net loss of $3.0 million, down from $3.8 million the previous year. The company expects its cash position to support operations until Q4 2026. Aprea is advancing its WEE1 and ATR inhibitor programs and plans to explore combination strategies for ATRN-119. R&D expenses decreased to $1.6 million from $2.8 million year-over-year. Analysts maintain a "strong buy" rating, with a median 12-month price target of $10.50, significantly above its recent closing price of $1.32.

Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers

Aprea Therapeutics Inc. has provided updates on its clinical trials for APR-1051 and ATRN-119. In the Phase 1 trial of APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at the 100 mg dose achieved stable disease in difficult-to-treat cancers. The trial has progressed to a 150 mg dose. For ATRN-119, the recommended Phase 2 dose is 1,100 mg. Results were presented at the AACR-NCI-EORTC conference on October 24, 2025. Future studies may explore APR-1051 in combination with checkpoint inhibitors.